GlobeImmune’s investigational hepatitis B virus (HBV) treatment, GS-4774, had mixed results in a Phase II trial, Reuters reports. The company is partnering with Gilead Sciences to develop the therapy, which in this randomized, open-label study was provided in three different injectable doses to 178 people taking antiviral treatment.

Those treated with the highest dose did not achieve the study’s primary goal, a reduction at week 24 in hepatitis B surface antigen (HBsAg), which is an indication of the strength of the infection. However, after 48 weeks, there was a significant reduction of the antigen among this group when compared with individuals only taking antiviral therapy.

GS-4774 proved generally safe and well tolerated. The primary adverse side effect was reactions at the injection site.

“We believe that this first Phase II trial of GS-4774 in virally suppressed patients suggests initial biologic activity at the highest dose tested,” said Timothy C. Rodell, MD, president and CEO of GlobeImmune, Inc. “We look forward to collaborating with our partner Gilead Sciences to identify potential next steps for GS-4774 in this patient population as well as to seeing the results from the second ongoing Phase II trial of GS-4774 in HBV treatment-naive patients.”

To read the Reuters article, click here.